Novo Nordisk (NYSE: NVO) Reports Strong Earnings and Raises 2026 Guidance
Novo Nordisk (NYSE: NVO)'s earnings per share of $0.89 surpassed analyst estimates of $0.73. Revenue reached $11.86 billion, exceeding the $11.08 billion estimate. The company raised its 2026 guidance, citing a better outlook for its obesity and diabetes drugs, including Wegovy. The Danish…